Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Article

May 17, 2022

New Study Reports Need to Monitor Public Interest in Shopping and Sales of Popular Puff Bar E-cigarette Brand

American Cancer Society researchers stress health interventions to continue reducing e-cigarette use among youth.

New research led by scientists atthe American Cancer Society (ACS) shows the need for continued surveillance of the changes in shopping interest and sales for Puff Bar, the most preferred brand of electronic cigarettes or e-cigarettes among youth in the United States. Public interest in shopping and sales of Puff Bar skyrocketed in 2020.The findings were published today in the journal Tobacco Control.

“Adoption of Puff Bar products in the U.S. may pose threats to public health and potentially exacerbate the youth vaping epidemic in the U.S.,“ said Dr. Anuja Majmundar, principal scientist, tobacco control research at the American Cancer Society, and lead author of the study. “E-cigarette use was at its highest peak among youth just less than two years ago. Our findings highlight how crucial it isto continuously monitor these products and prevent such unprecedented peaks in the future.”

Puff Bar is a leading e-cigarette brand vaping device pre-filled with synthetic

nicotine. The market for Puff Bar exploded in early 2020 after the U.S. Food and Drug Administration (FDA) published an enforcement guidance policy on unauthorized flavored cartridge-based e-cigarettes. Puff Bar, a single-use e-cigarette, has overtaken JUUL, a reusable e-cigarette, as the most preferred e-cigarette product among youth in the recent past.

In this study, researchers mapped trends in relative search volume (RSV) from Google shopping queries which would indicate the shopping interest in Puff Bar and JUUL products and their point-of-sales from March 2019 until May 2021. They mapped these trends in relation to significant regulatory, company sales policy announcements, and other events that may have potentially shaped the trajectory of these products:

Time period 1 (T1): Both JUUL and Puff Bar were sold and marketed as tobacco-derived nicotine-containing products (3/24/19 - 9/10/19).

Time period 2 (T2): Trump Administration announced plans to ban flavors; JUUL Labs’ voluntary announcement to halt online sales of its sweet and fruity products (9/11/19 - 1/1/20).

Time period 3 (T3): FDA published enforcement guidance policy on unauthorized flavored cartridge-based e-cigarettes; House approved flavored e-cigarette ban bill (1/2/20 - 6/14/20).

Time period 4 (T4): Puff Bar battled counterfeit sales, received an FDA warning letter, and suspended sales (6/15/20 - 3/1/21).

Time period 5 (T5): Puff Bar resumed sales as a synthetic nicotine-containing product (3/2/21 - 5/22/21).

After the Trump administration announced its plans to ban flavored e-cigarettes in September 2019 and JUUL Labs, Inc. decided to suspend the sales of its sweet and fruity flavored products in October 2019, JUUL’s shopping interest RSV and sales declined while Puff Bar’s shopping interest RSV peaked, and its sales increased, the study found. From the period following the FDA’s announcement of its enforcement guidance policy on unauthorized flavored cartridge-based e-cigarettes (March 2020 until May 2021,) JUUL’s shopping interest RSV and sales continued to decline. Puff Bar’s shopping interest RSV increased, and its sales peaked until lawmakers approved the flavored e-cigarette ban bill in February 2020. Puff Bar’s sales steeply declined following the suspension of its sales in February 2020. Between March 2, 2020, and May 15, 2020, the decline in Puff Bar sales slowed when they relaunched their products as synthetic nicotine-containing e-cigarettes, at a time when the FDA did not have regulatory authority over synthetic nicotine-containing tobacco products.

“However, we need more recent data to closely monitor whether Puff Bar sales increased after the relaunch,” warned Zheng Xue, senior associate scientist at the American Cancer Society and co-author.

As of April 2022, the FDA will regulate e-cigarette products containing synthetic nicotine. “These findings offer useful baseline measures to track the impact of the recent FDA regulatory authority over these products’ sales and public interest in the future,” said Majmundar.

The American Cancer Society’s advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN) advocated for closing the loophole that allowed products labeled as synthetic nicotine to circumvent FDA regulation and is calling on the FDA to enforce this new law.

Other ACS researchers of the study include senior author Dr. Nigar Nargis ‍and co-author, Dr. Samuel Asare .

Resources from the American Cancer Society about e-cigarettes and vaping can be found here.

# # #

About the American Cancer Society
The American Cancer Society is on a mission to free the world from cancer. We invest in lifesaving research, provide 24/7 information and support, and work to ensure that individuals in every community have access to cancer prevention, detection, and treatment. For more information, visit cancer.org.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Related Content
Advertisement
18% of patients on Medicaid were affected by the cancer drug shortages
November 2nd 2023

Patients on Medicaid Disproportionately Affected by Drug Shortage

Brielle Benyon
Patients insured by Medicaid may be more likely to be affected by the ongoing cancer drug shortage, according to a recent survey.
The following pull quote in a yellow box in front of an image of a doctor in a lab coat with a stethescope, writing on a clipboard: "However, despite the growing evidence of benefits, use of palliative care remains low in the U.S."
July 13th 2023

Navigating the Benefits, Access to Palliative Care for Advanced Cancer

Darlene Dobkowski, MA
Palliative care can benefit patients with advanced cancer by integrating advanced care planning, pain and symptom management and counseling, among other aspects.
Site Logo
March 2nd 2023

Cancer Statistics 2023

Site Logo
March 2nd 2023

Suicide Risk Among Individuals Diagnosed with Cancer in the United States, 2000-2016

Site Logo
February 27th 2023

New Study Shows Western Region has Highest Prostate Cancer Mortality Among White Men in U.S.; Black Men Face Highest Prostate Cancer Mortality Overall

American Cancer Society researchers stress increased attention and funding to identify reasons for this regional disparity in mortality and for rising incidence rates for all major genitourinary cancers including testicular and advanced-stage prostate cancers
Site Logo
February 25th 2023

Travel Time for Breast Cancer Screening Remains Long for Many Women in the U.S., New Study Shows

American Cancer Society researchers stress new programs to help geographic accessibility to cancer screening
Related Content
Advertisement
18% of patients on Medicaid were affected by the cancer drug shortages
November 2nd 2023

Patients on Medicaid Disproportionately Affected by Drug Shortage

Brielle Benyon
Patients insured by Medicaid may be more likely to be affected by the ongoing cancer drug shortage, according to a recent survey.
The following pull quote in a yellow box in front of an image of a doctor in a lab coat with a stethescope, writing on a clipboard: "However, despite the growing evidence of benefits, use of palliative care remains low in the U.S."
July 13th 2023

Navigating the Benefits, Access to Palliative Care for Advanced Cancer

Darlene Dobkowski, MA
Palliative care can benefit patients with advanced cancer by integrating advanced care planning, pain and symptom management and counseling, among other aspects.
Site Logo
March 2nd 2023

Cancer Statistics 2023

Site Logo
March 2nd 2023

Suicide Risk Among Individuals Diagnosed with Cancer in the United States, 2000-2016

Site Logo
February 27th 2023

New Study Shows Western Region has Highest Prostate Cancer Mortality Among White Men in U.S.; Black Men Face Highest Prostate Cancer Mortality Overall

American Cancer Society researchers stress increased attention and funding to identify reasons for this regional disparity in mortality and for rising incidence rates for all major genitourinary cancers including testicular and advanced-stage prostate cancers
Site Logo
February 25th 2023

Travel Time for Breast Cancer Screening Remains Long for Many Women in the U.S., New Study Shows

American Cancer Society researchers stress new programs to help geographic accessibility to cancer screening
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.